Skinny & Fit

Skinny & Fit is a research-based peptide stack that combines GLP-1(Sema), MOTS-c, and AOD-9604. These peptides are individually studied for their roles in metabolic processes, mitochondrial function, and tissue research. Their combination allows researchers to explore potential synergistic interactions in controlled environments.

Key Properties

GLP-1(Sema):

• A GLP-1 receptor agonist was studied for its role in glucose metabolism and cellular signalling pathways.
• The research investigates its interaction with metabolic processes and appetite regulation.

MOTS-c:

• A mitochondrial-derived peptide was explored for its effects on metabolic health and cellular energy regulation.
• Studies examine its involvement in stress responses and mitochondrial function.

AOD-9604:

• A human growth hormone (HGH) fragment was researched for its role in fat metabolism and cellular energy pathways.
• Investigated for its potential impact on cellular mechanisms of tissue remodelling.

Applications in Research

Skinny & Fit is a focus of laboratory research investigating:

• Mechanisms of glucose metabolism and insulin sensitivity (GLP-1(Sema)).
• Cellular energy pathways and mitochondrial function (MOTS-c).
• Fat metabolism and tissue-specific effects (AOD-9604).

Research is conducted in laboratories to expand understanding of the biochemical pathways these peptides influence. 

Component Research Breakdown

GLP-1(Sema) — GLP-1 Receptor Agonist

GLP-1(Sema) is a glucagon-like peptide-1 (GLP-1) receptor agonist studied for its role in glucose-dependent insulin secretion, appetite regulation via CNS signaling, and gastric motility modulation. Preclinical research demonstrates its ability to reduce body weight in rodent models through distributed neural pathways. Researchers studying metabolic syndrome, insulin resistance, or GLP-1 receptor pharmacology use GLP-1(Sema) as a reference standard compound. See the GLP-1(Sema) product page for standalone research options.

MOTS-C — Mitochondrial-Derived Peptide

MOTS-C is encoded within the mitochondrial genome and acts as a retrograde signal to the nucleus, influencing metabolic gene expression. Research has demonstrated MOTS-C's role in activating the AMPK pathway and regulating folate-linked nucleotide metabolism. In rodent studies, MOTS-C administration improved insulin sensitivity and reduced obesity-related metabolic dysfunction. See the MOTS-C product page for additional research context.

AOD-9604 — C-Terminal HGH Fragment

AOD-9604 is a synthetic peptide comprising the C-terminal amino acids 176–191 of human growth hormone. Research focuses on its selective lipolytic activity — specifically its ability to stimulate fat metabolism via beta-adrenergic receptor-dependent mechanisms without the insulin-desensitizing effects of full-length HGH. In obese mouse models, AOD-9604 demonstrated significant reductions in adipose tissue without affecting IGF-1 levels. See the AOD-9604 product page for more information.

Synergistic Research Rationale

The combination of GLP-1(Sema), MOTS-C, and AOD-9604 in a single research blend enables investigation of three distinct but complementary metabolic axes:

• Central appetite regulation via GLP-1R signaling (GLP-1(Sema))
• Mitochondrial energy metabolism via AMPK/AICAR pathways (MOTS-C)
• Peripheral lipolysis via beta-adrenergic adipose signaling (AOD-9604)

This multi-pathway approach makes the Skinny & Fit blend a useful tool for researchers studying the intersection of CNS, mitochondrial, and adipose biology in metabolic disease models. For guidance on designing multi-peptide research protocols, consult our Stacking Peptides Research Guide.

Storage and Handling Instructions

• Store peptides in lyophilized form at -4°F (-20°C) or lower to maintain stability.
• Protect from light, moisture, and excessive heat.
• Discard unused or reconstituted solutions immediately after use following research protocols.

Safety Information

This product is intended for research purposes. You must:

• Follow institutional safety protocols during handling and storage.
• Use appropriate protective equipment.
• Ensure compliance with proper disposal guidelines for materials.

Frequently Asked Questions

What is Skinny & Fit?
Skinny & Fit is a peptide stack combining GLP-1(Sema), MOTS-c, and AOD-9604 to research metabolic and cellular processes.

How should Skinny & Fit be stored?
Store at -4°F (-20°C) in a light-protected environment. Reconstituted solutions should be used immediately following laboratory protocols.

What are the primary research focuses of Skinny & Fit?
Research explores GLP-1(Sema)’s effects on glucose metabolism, MOTS-c’s role in mitochondrial function, and AOD-9604’s impact on fat metabolism.

Frequently Asked Questions

What is the Skinny and Fit blend and how is it used in research?

Skinny and Fit is a research peptide blend combining GLP-1(Sema) (a GLP-1 receptor agonist), MOTS-c (a mitochondrial-derived peptide), and AOD-9604 (a synthetic C-terminal fragment of human growth hormone). Each component targets distinct metabolic pathways, and their combination is studied in preclinical models to explore potential complementary mechanisms in metabolic research. All experimental work is conducted in controlled laboratory settings.

What metabolic pathways does each component target in research?

GLP-1(Sema) activates GLP-1 receptors in the CNS and peripheral tissues to modulate appetite signaling and glucose metabolism. MOTS-c acts through the folate-AICAR-AMPK pathway to influence mitochondrial energy metabolism and insulin sensitivity. AOD-9604, the C-terminal hGH fragment, has been studied for selective lipolytic activity via beta-adrenergic receptor modulation in obese rodent models. These mechanisms represent distinct but potentially complementary metabolic regulatory systems.

How should the Skinny and Fit blend be stored for laboratory research?

All three peptide components should be stored lyophilized at -20 degrees C or lower, protected from light and moisture. Each component should be reconstituted separately with sterile bacteriostatic water immediately before use in the research protocol. Post-reconstitution solutions should be handled under appropriate biosafety conditions and used promptly.

What purity standards apply to each component of the blend?

Each peptide component (GLP-1(Sema), MOTS-c, and AOD-9604) should individually demonstrate greater than or equal to 98% purity by HPLC analysis with mass spectrometry identity confirmation. In-house purity testing ensures batch consistency.

What distinguishes the combination of GLP-1 agonism, mitochondrial peptide activity, and lipolytic GH fragments in research?

Each component addresses distinct metabolic regulatory nodes: GLP-1(Sema)'s CNS and peripheral GLP-1R signaling, MOTS-c's mitochondrial-nuclear cross-signaling through AMPK, and AOD-9604's peripheral adipose tissue effects. Combining these mechanisms in a single research protocol enables investigation of complementary pathways in preclinical metabolic models under controlled experimental conditions.

What preclinical research has characterized each component individually?

GLP-1(Sema) has been studied in rodent obesity and diabetes models demonstrating GLP-1R-mediated weight and glycemic regulation. MOTS-c was identified in 2015 as a mitochondrial regulator of metabolic homeostasis and insulin sensitivity. AOD-9604 has been characterized in obese mouse models for its lipolytic effects via the C-terminal hGH fragment mechanism. These studies provide the individual pharmacological basis for each component's research use.

References

1. Gabery S, Salinas CG, Paulsen SJ, et al. “GLP-1(Sema) lowers body weight in rodents via distributed neural pathways.” JCI Insight. 2020;5(6):e133429.. PubMed
2. Lee C, Zeng J, Drew BG, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab. 2015;21(3):443-54.. PubMed
3. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.” Horm Res. 2000;53(6):274-8.. PubMed
4. Drucker DJ. “GLP-1 physiology informs the pharmacotherapy of obesity.” Mol Metab. 2022;57:101351.. PubMed